#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Non-small cell lung cancer metastatic Asthma Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Thrombocytopenia Candida infection Allogenic stem cell transplantation Hyperinsulinism Waldenstrom's macroglobulinaemia refractory Anti-myelin-associated glycoprotein associated polyneuropathy Ehlers-Danlos syndrome Oesophageal adenocarcinoma stage II Dermatomyositis Chronic kidney disease Immune thrombocytopenia Pericarditis PIK3CA-activated mutation Inborn error of metabolism Mitochondrial DNA depletion More trials…

    Learn about Rare Diseases

    Choroid melanoma Activated PI3 kinase delta syndrome – Trials in Disease Glomerulonephritis membranous – Treatment Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome Waldenstrom’s macroglobulinaemia – Life with Disease Pituitary-dependent Cushing’s syndrome Ewing’s sarcoma metastatic – Life with Disease Acquired haemophilia – Treatment Prolymphocytic leukaemia – Treatment Thrombotic thrombocytopenic purpura – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    COLESEVELAM HYDROCHLORIDE Resiniferatoxin Human Fibrinogen PEGVISOMANT Tolvaptan Fluorouracil Sodium Alnus Glutinosa Pollen Asciminib Dulaglutide Formoterol Fumarate Dihydrate Oritavancin Semaglutide Fluocinolone Acetonide Futibatinib Olaptesed Pegol Mometasone Cannabidiol ALXN2420 Azelastine Antipsychotics More therapies…

    Learn about Your Condition

    Aplastic anaemia Breast cancer recurrent Bone marrow failure Schizophreniform disorder Intestinal infarction Gastrointestinal melanoma Traumatic pain Renal cell carcinoma Ehlers-Danlos syndrome Gastric cancer Chorioretinitis Hypertriglyceridaemia Uveitis Pyelonephritis acute Hypoparathyroidism More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Dermatitis atopic

  • Study on Tralokinumab and Topical Corticosteroids for Children and Infants with Moderate-to-Severe Atopic Dermatitis

    Not recruiting

    4 1 1
    Investigated Drugs:
    • Tralokinumab
    Belgium Croatia Czechia Denmark Germany Ireland +6

  • Study on Tralokinumab for Moderate-to-Severe Atopic Hand Eczema in Patients Needing Systemic Therapy

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Tralokinumab
    Belgium Czechia France Germany The Netherlands Poland +3

  • Study on the Effects of GSK1070806 Injection in Adults with Moderate to Severe Atopic Dermatitis

    Not recruiting

    2 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Humanised Igg1 Kappa Monoclonal Antibody Against Interleukin 18
    Bulgaria Czechia France Germany Greece Italy +2

  • Study on the Effectiveness and Safety of ANB032, Betamethasone Dipropionate, and Hydrocortisone for Patients with Moderate to Severe Atopic Dermatitis

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Anb032
    • Betamethasone Dipropionate
    • Hydrocortisone
    Czechia Poland

  • Study on the Safety and Effects of IMG-007 for Adults with Moderate to Severe Atopic Dermatitis

    Not recruiting

    1 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Img-007
    Germany Poland

  • Study on Rezpegaldesleukin for Treating Moderate-to-Severe Atopic Dermatitis in Adults

    Not recruiting

    2 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Rezpegaldesleukin
    Bulgaria Croatia Czechia Germany Hungary Poland +1
Previous Page
1 … 7 8 9 10 11 … 14
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!